sitagliptin hydrochloride

sitagliptin hydrochloride (BRYNOVIN) is an FDA-listed pharmaceutical active ingredient. Route of administration: oral. Current US regulatory status: approved.

BRYNOVIN is a marketed brand name for sitagliptin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

sitagliptin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.